Jiangsu GDK Biotechnology Co Ltd Total Assets
Jiangsu GDK Biotechnology Co Ltd total assets. Based on the latest financial reports, Jiangsu GDK Biotechnology Co Ltd (688670) holds total assets worth CN¥1.36 Billion CNY (≈ $198.42 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Jiangsu GDK Biotechnology Co Ltd (688670) total market value for the company's overall valuation and market capitalisation.
Total Assets of Jiangsu GDK Biotechnology Co Ltd (2017–2025)
Total assets of Jiangsu GDK Biotechnology Co Ltd from 2017 to 2025. This chart illustrates how Jiangsu GDK Biotechnology Co Ltd's total assets have evolved over time, based on quarterly financial data. See Jiangsu GDK Biotechnology Co Ltd stock price for real-time trading data and today's change.
Jiangsu GDK Biotechnology Co Ltd - Asset Composition Analysis
Jiangsu GDK Biotechnology Co Ltd Total Assets Breakdown (December 2025)
Jiangsu GDK Biotechnology Co Ltd total assets breakdown as of December 2025. Jiangsu GDK Biotechnology Co Ltd's total assets of CN¥1.36 Billion consist of 25.1% current assets and 74.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.9% |
| Accounts Receivable | CN¥139.74 Million | 9.9% |
| Inventory | CN¥16.33 Million | 1.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥80.53 Million | 5.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Jiangsu GDK Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 688670 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu GDK Biotechnology Co Ltd's current assets represent 25.1% of total assets in 2025, an increase from 4.5% in 2017.
- Cash Position: Cash and equivalents constituted 5.9% of total assets in 2025, up from 0.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 9.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 9.9% of total assets.
Jiangsu GDK Biotechnology Co Ltd Competitors by Total Assets
Key competitors of Jiangsu GDK Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Jiangsu GDK Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.52 | 2.59 | 0.90 |
| Quick Ratio | 1.36 | 2.32 | 0.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥105.62 Million | CN¥332.04 Million | CN¥-44.18 Million |
Jiangsu GDK Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangsu GDK Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.79 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | -7.5% |
| Total Assets | CN¥1.42 Billion |
| Market Capitalization | $231.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu GDK Biotechnology Co Ltd's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Jiangsu GDK Biotechnology Co Ltd's assets decreased by 7.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Jiangsu GDK Biotechnology Co Ltd (2017–2025)
The table below shows the annual total assets of Jiangsu GDK Biotechnology Co Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.42 Billion ≈ $207.59 Million |
-7.46% |
| 2024-12-31 | CN¥1.53 Billion ≈ $224.31 Million |
-6.05% |
| 2023-12-31 | CN¥1.63 Billion ≈ $238.75 Million |
-10.68% |
| 2022-12-31 | CN¥1.83 Billion ≈ $267.31 Million |
+4.12% |
| 2021-12-31 | CN¥1.75 Billion ≈ $256.74 Million |
+125.52% |
| 2020-12-31 | CN¥777.98 Million ≈ $113.84 Million |
+95.82% |
| 2019-12-31 | CN¥397.30 Million ≈ $58.14 Million |
+27.59% |
| 2018-12-31 | CN¥311.39 Million ≈ $45.57 Million |
+4.47% |
| 2017-12-31 | CN¥298.06 Million ≈ $43.62 Million |
-- |
About Jiangsu GDK Biotechnology Co Ltd
Jiangsu Gdk Biological Technology Co., Ltd engages in the research, development, production, and sale of human vaccines. It offers quadrivalent influenza virus split vaccines. The company human vaccine products are used for the prevention of various infectious diseases, including influenza, rabies, chickenpox, shingles, and pneumonia. Jiangsu Gdk Biological Technology Co., Ltd was founded in 2008… Read more